• Completed $203 million placement, strengthening balance sheet
• Co-PSMA trial achieved primary endpoint, showing enhanced diagnostic performance of 64Cu-SAR-bisPSMA
• Signed copper-67 supply agreement, expanding US-based supplier network

Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company, released its quarterly activity report and Appendix 4C for the three months ending 30 September 2025. Key highlights include the successful completion of a $203 million placement with institutional investors, strengthening the company's balance sheet to $253.1 million and enabling the continued progression of its clinical development plans. The company's lead product, 64Cu-SAR-bisPSMA, achieved a significant milestone with the Co-PSMA investigator-initiated trial reaching its primary endpoint. The trial demonstrated a significantly higher number of prostate-specific membrane antigen (PSMA)-positive prostate cancer lesions detected using 64Cu-SAR-bisPSMA compared to the standard-of-care 68Ga-PSMA-11 positron emission tomography/computed tomography (PET/CT) in patients with biochemical recurrence and low prostate-specific antigen (PSA) levels. This data further validates 64Cu-SAR-bisPSMA as a best-in-class PSMA PET imaging agent and supports the company's ongoing registrational trials, AMPLIFY and CLARIFY. Additionally, Clarity announced the signing of a supply agreement with Nusano for copper-67, expanding its growing network of US-based suppliers, including NorthStar and the Idaho State University Idaho Accelerator Center. This secures the company's supply chain for its theranostic pipeline, which includes the 67Cu-SAR-bisPSMA therapy product. Clarity also presented pre-clinical data on its pan-cancer theranostic, 64/67Cu-SAR-bisFAP, at the World Molecular Imaging Conference 2025, highlighting its potential to target a range of cancer indications.

Clarity remains well-funded with a cash position of $253.1 million as of 30 September 2025, providing the company with the resources to continue progressing its clinical development plans.

Clarity is focused on advancing its key product, SAR-bisPSMA, through registrational trials for diagnostic applications and progressing its theranostic program into a Phase III trial. The company is also dedicated to growing its pipeline of products in a range of indications through collaborations with key opinion leaders and research organizations, including the recently progressed SAR-bisFAP agent.